Back to News
Market Impact: 0.42
Amneal Pharma Gains FDA Approval For Lanreotide Injection
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Amneal Pharmaceuticals received FDA approval for its lanreotide injection, 120 mg/0.5 mL, in a sterile single-dose prefilled syringe. The product references SOMATULINE Depot and is expected to be launched immediately, creating a new approved product opportunity for Amneal in the U.S. market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
AMRX0.78
More News
- AI stocks fall as Texas governor result raises data center risks
- Trump promised every adult $5,000 if Republicans kept control of Congress. Thanks to Democrats, taxpayers won’t have to pay up and blow up the debt
- ‘Lawyer up’: Democrats take the House, and warn Trump’s family businesses are first in line for subpoenas
- Democratic Party flips US Senate in 2026 midterm elections
- Investors poised for possible Democratic gains in Congress as US awaits election results
- Texas race results could kick AI trade while it's already down